Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

Contrary to the belief that great products sell themselves, truly transformative ideas require more marketing, not less. This is because they demand significant behavioral change, and marketing must provide the psychological reassurance for consumers to overcome the hurdle of adoption.

When introducing a disruptive model, potential partners are hesitant to be the first adopter due to perceived risk. The strategy is to start with small, persistent efforts, normalizing the behavior until the advantages become undeniable. Innovation requires a patient strategy to overcome initial industry inertia.

CRISPR reframes its commercial strategy away from traditional drug launches. By viewing gene editing as a 'molecular surgery,' the company adopts a go-to-market approach similar to medical devices, focusing on paradigm shifts in hospital procedures and physician training.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

The increasing volume of new therapies requires pharma companies to stop treating each launch as a unique event. Instead, they must develop a scalable, repeatable, and excellent launch capability to handle the future pipeline efficiently and consistently.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.

Applying traditional, broad primary care launch strategies to highly targeted specialty therapies is a major risk. The complexity of stakeholders and decision-making in areas like oncology means old playbooks can make a company's efforts completely irrelevant.

A primary driver of recent pharma launch failures is underinvestment in pre-launch market conditioning. Cautious investors and tighter budgets mean companies have fewer resources to tell their scientific story effectively before launch. This delayed and underfunded approach has a dramatic negative impact on commercial success.